Safety monitoring in the vaccine adverse event reporting system (VAERS)

TT Shimabukuro, M Nguyen, D Martin, F DeStefano - Vaccine, 2015 - Elsevier
Abstract The Centers for Disease Control and Prevention (CDC) and the US Food and Drug
Administration (FDA) conduct post-licensure vaccine safety monitoring using the Vaccine …

Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction

Y Segal, Y Shoenfeld - Cellular & molecular immunology, 2018 - nature.com
Since the early 1800s vaccines have saved numerous lives by preventing lethal infections.
However, during the past two decades, there has been growing awareness of possible …

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women

EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …

[HTML][HTML] Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)

LE Markowitz, EF Dunne, M Saraiya, HW Chesson… - MMWR Recomm …, 2014 - cdc.gov
This report summarizes the epidemiology of human papillomavirus (HPV) and associated
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in …

L Arnheim-Dahlström, B Pasternak, H Svanström… - Bmj, 2013 - bmj.com
Objective To assess the risk of serious adverse events after vaccination of adolescent girls
with quadrivalent human papillomavirus (qHPV) vaccine. Design Register based cohort …

[BOOK][B] Deadly choices: How the anti-vaccine movement threatens us all

PA Offit - 2015 - books.google.com
Page 1 “The very best antidote to vaccine-related misinformation: the writings of vaccinologist
Paul Offit. No one is better at reducing anti-vaccine claims to intellectual rubble.” —New …

Present status of human papillomavirus vaccine development and implementation

R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Safety of human papillomavirus vaccines: an updated review

A Phillips, C Patel, A Pillsbury, J Brotherton… - Drug safety, 2018 - Springer
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71
countries. Unfortunately, uptake has been impacted in some countries by reduced …

[HTML][HTML] Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation

GD Zimet, Z Rosberger, WA Fisher, S Perez… - Preventive …, 2013 - Elsevier
Objective Human papillomavirus (HPV) vaccine uptake in many countries has been sub-
optimal. We examine several issues associated with non-vaccination that have received …

An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015

M Vichnin, P Bonanni, NP Klein… - The Pediatric …, 2015 - journals.lww.com
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …